49 results on '"Sagnelli, E"'
Search Results
2. Clinical and virological characteristics associated with severe acute hepatitis B
3. The aetiology of chronic hepatitis in Italy: results from a multicentre national study
4. Characteristics of liver cirrhosis in Italy: results from a multicenter national study
5. Risk management of HBsAg or anti-HCV positive healthcare workers in hospital
6. Liver microRNA hsa-miR-125a-5p may exert an oncosuppressor effect on HCC
7. THU-151 - Impact of Occult HBV Infection in Hepatocellular Carcinoma Presentation in HCV-Related Cirrhosis
8. The impact of the CB2-63 polymorphism on the histological presentation of chronic hepatitis B
9. P0628 : A high genetic heterogeneity in HBsAg can affect immunogenicity in acute hepatitis B infection
10. P0578 : HBsAg negative anti-HBc positive serology increases the risk of HCC in chronic hepatitis patients: A meta-analysis
11. P0573 : A strategy to favor the access of irregular and refugee migrants to a screening program for HBV, HCV AND HIV infection
12. A STRATEGY TO FAVOR THE ACCESS OF IRREGULAR AND REFUGEE MIGRANTS TO A SCREENING PROGRAM FOR HBV, HCV AND HIV INFECTION
13. HBsAg NEGATIVE ANTI-HBc POSITIVE SEROLOGY INCREASES THE RISK OF HCC IN CHRONIC HEPATITIS PATIENTS: A META-ANALYSIS
14. A high HBsAg genetic complexity can influence HBV immunogenicity in the setting of acute infection
15. THE TM6SF2 E167 K VARIANT IS AN INDEPENDENT PREDICTOR OF SEVERE LIVER STEATOSIS IN CHRONIC HEPATITIS C
16. PNPLA3 variant is an independent predictor of severe steatosis in patients with cronic hepatitis C and HIV infection
17. Impact of occult HBV infection in HCC presentation in HCV-related cirrhosis
18. Cannabinoid receptor 2-63 Qq variant is associated with persistently normal aminotransferase serum levels in chronic hepatitis C
19. Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: A meta-analysis on role of response predictors
20. T-16 Liver microRNA hsa-miR-125a-5p in HBV chronic infection: correlation with HBV replication and disease progression
21. T-05 Cannabinoid receptor 2 (CB2) 63 QQ variant is associated with a severe histological activity index in patients with chronic hepatitis C
22. T-10 Acute exacerbation of chronic hepatitis C: clinical presentation, outcome and response to anti-HCV treatment
23. OC-27 An open, randomized, multicentre trial to evaluate efficacy and safety of a 24 week-course of Peg-interferon α-2b versus a 12 week-course of Peg-Interferon α-2b alone or plus ribavirin in patients with acute hepatitis C
24. T-14 Virological and clinical impact of anti-HBV nucleos(t)ide analogues in cirrhotic patients with HBV-HCV coinfection
25. OC-12 Identification of lamivudine resistant HBV strain rt204V/I in acute hepatitis B in Italy
26. OC1 HBV AND IMMIGRANTS: A SIMIT MULTICENTER CROSS-SECTIONAL STUDY
27. OC.09.7: PEG-IFN FOR HEPATITIS C IN CLINICAL PRACTICE: RESULTS OF THE RETROSPECTIVE PHASE OF THE AIFA STUDY
28. F-6 Efficacy and tolerability of peginterferon a-2a and a-2b in patients with chronic hepatitis C by genotype 1: A meta-analysis
29. F-42 OptiB Italian multicenter prospective study on tenofovir in suboptimal responders to ADV or ADV/LAM treatment: 96 weeks results on efficacy and tolerance
30. T-38 PEG-IFN for hepatitis C in clinical practice: Results of the retrospective phase of the AIFA study
31. OC-34 HCV replication in patients with onco-haematological diseases
32. Progression of liver histological lesions in HIV/HCV coinfection
33. Adefovir and lamivudine combination therapy is superior to ADV monotherapy for lamivudine-resistant patients with HBeAG-negative chronic hepatitis B
34. P.414 Clinical course of chronic hepatitis in HCV/HIV coinfected patients: the lesson from sequential liver biopsies
35. P.412 Impact of occult HBV infection in HIV patients naive for anti-retroviral therapy
36. P.403 Clinical and virological improvement of HBV or HCV related chronic hepatitis with concomitant HAV infection
37. P.316 Hepatitis A infection in Naples and Caserta areas during the period 2000–2004: is the virus normally circulating or it has been re-introduced?
38. P.216 Molecular analysis of genetic variability and epitope stability in a type 1b recurrent HCV infection
39. P.195 Virological and clinical aspect of occult HBV infection in patient with chronic hepatitis C: a multicentre study
40. P.152 Anti-HCV IgG avidity index in acute hepatitis C
41. Trends of aetiological factors of hepatocellular carcinoma in Italy
42. Long-term lymphoblastoid interferon-α therapy for non-cirrhotic chronic hepatitis C: an Italian multicentre study on dose and duration of IFNα treatment
43. HBV and HCV chronic hepatitis and cirrhosis
44. Complications following percutaneous liver biopsy: A multicentre retrospective study on 68 276 biopsies
45. Effect of prednisone followed by interferon (IFN) in children with chronic hepatitis B
46. Interaction between HCV, HBV and HDV infection in HBsAg chronic carriers
47. Anti-HCV in patients wtih HBsAg positive or cryptogenic chronic hepatitis: Comparison between 1st and 2nd generation tests
48. HCV infection in drug addicts: Relationship with HIV and other infections
49. Treatment and survival rates of large series of hepatocellular carcinoma (HCC) observed in Naples
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.